IRAK-M Modulation for Dry AMD Early Intervention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly, with current treatments lacking effective early intervention options for dry AMD, leading to severe visual impairment or blindness.

Innovation Solution

The development of an agent that increases the expression of Interleukin 1 receptor-associated kinase-M (IRAK-M) in retinal pigment epithelial (RPE) cells, either by introducing exogenous IRAK-M or using nucleic acids, vector virions, or small molecules to enhance endogenous expression, thereby promoting cellular protection and reducing inflammatory responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for AMD, then late-stage wet AMD can be managed, but early intervention for dry AMD is unavailable leading to severe visual impairment

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidlack of early intervention

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by developing agents that can be administered in early dry AMD stages to prevent progression to late-stage disease. The IRAK-M modulating agents are designed to intervene before severe visual impairment occurs, addressing the timing gap in current treatment protocols where only late-stage wet AMD has available therapies.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If inflammatory responses are allowed to proceed unchecked, then immune response can clear pathogens, but excessive inflammation accelerates tissue ageing and AMD progression

Engineering Contradiction:

Improveimmune defense functionVSAvoidexcessive inflammation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modulating the expression levels of IRAK-M protein in RPE cells. By adjusting this specific molecular parameter, the patent shifts the balance of inflammatory responses - enhancing anti-inflammatory signaling through increased IRAK-M expression to prevent excessive inflammation-driven AMD progression, while preserving necessary immune defense functions.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If RPE cells are exposed to oxidative stress, then normal metabolic processes continue, but mitochondrial metabolism is altered and cell function is impaired

Engineering Contradiction:

Improvenormal cell functionVSAvoidoxidative stress

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies beforehand cushioning by using IRAK-M modulating agents to pre-protect RPE cells against oxidative stress damage. The agents are designed to enhance cellular defense mechanisms before oxidative stress fully impairs mitochondrial metabolism and cell function, creating a protective buffer against age-related oxidative damage accumulation.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Data Source

PatentUS20250177573A1Materials & Methods for Treatment of Macular Degeneration

Publication Date: 2025.06.05 UNIV OF BRISTOL

AI summary

The present invention relates to an agent that increases expression of IRAK-M and/or activity of IRAK-M for use in a method of treatment or prophylaxis of macular degeneration in a subject. The agent may be one or more of a small molecule, a nucleic acid, a vector virion, a polypeptide, a nucleic acid system, a viral vector system, or a pharmaceutical composition.